VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), a life science company focused on the development and commercialization of genomic-based diagnostic and screening tests for cancer and cardiovascular disease, is pleased to welcome Sandeep S. Davé, M.D. of Duke University to its lymphoma collaboration.  MBI and Duke entered into a research collaboration and option agreement in March 2007.

Dr. Davé came to Duke this summer as an Assistant Professor in the Institute for Genome Sciences and Policy and in the Department of Medicine's Division of Medical Oncology.  Prior to joining Duke, Dr. Davé was a postdoctoral fellow at the laboratory of Louis Staudt at the National Cancer Institute.  At the Staudt laboratory, Dr. Davé was involved in translational research aimed at using gene expression profiling to understand the role of differentially activated molecular pathways in non-Hodgkin lymphoma.

Dr. Davé has authored numerous articles in peer reviewed journals, including two as lead author in the New England Journal of Medicine, "Molecular Diagnosis of Burkitt's lymphoma" and "Prediction of Survival in Follicular Lymphoma based on Molecular Features of Tumor-Infiltrating Immune Cells".

Dr. Davé attended graduate school, medical school and completed his residency in internal medicine at Northwestern University.  He completed a fellowship in hematology and medical oncology at the National Institutes of Health.

"I am very excited to work with Med BioGene and to expand upon the work that I undertook at the National Cancer Institute.  Gene expression profiling has demonstrated that lymphoma types that were previously regarded as homogenous can harbor subgroups that are dramatically different in their biology and responses to therapy.  Such studies could form the basis for risk stratification and tailored therapies that are most likely to benefit molecularly defined subgroups of patients" noted Dr. Davé.

"Dr. Davé is a world renowned expert in the research of gene expression profiling of lymphoma and we are very pleased to be working with him and Dr. David A. Rizzieri, Associate Professor of Medicine and Director, Hematologic Malignancy Program at Duke University.  Our collaboration with Duke is central to the development of our first genomic-based clinical laboratory diagnostic test for lymphoma, LymphExpress Dx™" said Erinn B. Broshko, Chief Executive Officer of MBI.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic and screening tests for cancer and cardiovascular disease.  MBI develops these tests by identifying the genes, known as "biomarkers," which indicate the presence of disease.  The development of these tests is the first step towards personalized medicine and will replace the conventional "one drug fits all" approach to disease management.
 
Expected benefits include:

•   more accurate, quicker and less invasive diagnosis;

•   tailoring of treatment decisions to the needs of each patient by outlining a patient's genetic profile, thus making treatment more effective and reducing healthcare costs by minimizing the treatment of non-responders; and

•   prioritizing of genomic biomarkers for use as potential therapeutic targets and to validate the effectiveness of specific therapeutics.

MBI is currently developing tests for lymphoma, leukemia and cardiovascular disease through the following products:  LymphExpress Dx™, LeukExpress Dx™ and CardioExpress Dx™.

For corporate information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com
www.medbiogene.com

For investor relations information, please contact:

The Howard Group Inc.
(888) 221-0915
info@howardgroupinc.com
www.howardgroupinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation.  Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI’s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. MBI’s forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.